CPHI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -69.14% compared to China Pharma Holding's net margin of -49.65%. China Pharma Holding's return on equity of -61.79% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

China Pharma Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that NovaBay Pharmaceuticals has higher upside potential than China Pharma Holding, analysts believe NovaBay Pharmaceuticals is more attractive than China Pharma Holding.

China Pharma Holding has a beta of 0.789, which suggesting that the stock is 21.096% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

China Pharma Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holding pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

China Pharma Holding quarterly revenues are $1.1M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. China Pharma Holding's net income of -$785.6K is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, China Pharma Holding's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holding is 0.94x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -69.14% compared to China Pharma Holding's net margin of --. China Pharma Holding's return on equity of -61.79% beat Oragenics's return on equity of --.

China Pharma Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1998.11%. Given that Oragenics has higher upside potential than China Pharma Holding, analysts believe Oragenics is more attractive than China Pharma Holding.

China Pharma Holding has a beta of 0.789, which suggesting that the stock is 21.096% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

China Pharma Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holding pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

China Pharma Holding quarterly revenues are $1.1M, which are larger than Oragenics quarterly revenues of --. China Pharma Holding's net income of -$785.6K is higher than Oragenics's net income of -$2.2M. Notably, China Pharma Holding's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holding is 0.94x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -69.14% compared to China Pharma Holding's net margin of --. China Pharma Holding's return on equity of -61.79% beat Theriva Biologics's return on equity of --.

China Pharma Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1367.51%. Given that Theriva Biologics has higher upside potential than China Pharma Holding, analysts believe Theriva Biologics is more attractive than China Pharma Holding.

China Pharma Holding has a beta of 0.789, which suggesting that the stock is 21.096% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

China Pharma Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holding pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

China Pharma Holding quarterly revenues are $1.1M, which are larger than Theriva Biologics quarterly revenues of --. China Pharma Holding's net income of -$785.6K is higher than Theriva Biologics's net income of -$4.3M. Notably, China Pharma Holding's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holding is 0.94x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Yubo International Biotech has a net margin of -69.14% compared to China Pharma Holding's net margin of -11740.4%. China Pharma Holding's return on equity of -61.79% beat Yubo International Biotech's return on equity of --.

China Pharma Holding has a consensus price target of --, signalling downside risk potential of --. On the other hand Yubo International Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that China Pharma Holding has higher upside potential than Yubo International Biotech, analysts believe China Pharma Holding is more attractive than Yubo International Biotech.

China Pharma Holding has a beta of 0.789, which suggesting that the stock is 21.096% less volatile than S&P 500. In comparison Yubo International Biotech has a beta of 3.981, suggesting its more volatile than the S&P 500 by 298.105%.

China Pharma Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Yubo International Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holding pays -- of its earnings as a dividend. Yubo International Biotech pays out -- of its earnings as a dividend.

China Pharma Holding quarterly revenues are $1.1M, which are larger than Yubo International Biotech quarterly revenues of $3.5K. China Pharma Holding's net income of -$785.6K is lower than Yubo International Biotech's net income of -$435.6K. Notably, China Pharma Holding's price-to-earnings ratio is -- while Yubo International Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holding is 0.94x versus 12.99x for Yubo International Biotech. Usually stocks with elevated PS ratios are considered overvalued.